Background:

VEGFR tyrosine kinase inhibitor II is a pyridinyl-anthranilamide compound that inhibits the kinase activities of VEGFR2 (KDR), VEGFR1 (FLT1), and c-Kit (IC50s = 20, 180, and 240 nM, respectively).1 It displays minimal activity against c-Src and EGFR (IC50s = 7 and 7.3 μM, respectively) and is inactive against Cdk1, c-Met, IGF-1R, and PKA (IC50s > 10 μM).1 VEGFR tyrosine kinase inhibitor II has been investigated for its potential to inhibit tumor induced angiogenesis.[1]

Reference:
[1] Furet, P., Bold, G., Hofmann, F., et al. Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching. Bioorganic & Medicinal Chemistry Letters 13(18), 2967-2971 (2003).